Prazosin for Treating Noncombat Trauma Post-Traumatic Stress Disorder

Status Terminated

Clinical Trial Summary

This study will evaluate the effectiveness of prazosin in treating post-traumatic stress disorder caused by noncombat trauma in individuals taking selective serotonin reuptake inhibitors.

Clinical Trial Description

Post-traumatic stress disorder (PTSD) is an anxiety disorder that can develop after exposure to a terrifying event in which grave physical harm occurred or was threatened. People with PTSD have persistent frightening thoughts and memories of their past ordeal and often feel emotionally numb, especially with people to whom they were once close. PTSD was first recognized in male combat veterans. Today, however, the majority of people who have PTSD are young women who have experienced non combat-related trauma, such as sexual or physical assault or a life-threatening illness or accident. The disorder can be short-lived, but PTSD can also become chronic, with long lasting symptoms that are often treatment-resistant, possibly causing severe functional disability. Frequent trauma-related nightmares and other debilitating sleep disruptions are examples of chronic PTSD symptoms for which an effective treatment has not been developed. Sertraline and paroxetine, both selective serotonin reuptake inhibitors (SSRIs), are the only drugs approved by the FDA for treating PTSD. Neither of them, however, has been effective in reducing PTSD-related sleep disruption. Studies have shown that the drug prazosin has been effective in reducing distressing trauma-related nightmares in older male combat veterans. This study will evaluate the effectiveness of prazosin in treating post-traumatic stress disorder caused by noncombat trauma in individuals already being treated with SSRIs.

Participants in this double-blind study will first undergo 12 weeks of treatment with psychotherapy and a standard SSRI. After 12 weeks, participants will be randomly assigned to receive either prazosin or placebo in addition to psychotherapy and standard SSRI treatment for a total of 8 weeks. Study visits will occur weekly for the first 12 weeks, and then at Weeks 1, 2, 4, 6, and 8 during the 8-week phase. Additionally, follow-up visits will be held 4 and 18 weeks post-intervention. PTSD symptoms, disorder severity, and frequency of sleep disturbances will be assessed. ;

Study Design

Related Conditions & MeSH terms

Disease
Post-Traumatic Stress Disorder
Sleep Initiation and Maintenance Disorders
Stress Disorders, Post-Traumatic
Stress Disorders, Traumatic

Clinical Trial Details

NCT number	NCT00183430
Study type	Interventional
Source	Seattle Institute for Biomedical and Clinical Research
Contact
Status	Terminated
Phase	N/A
Start date	October 2003
Completion date	December 2010

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT04317820` - Deep Brain Reorienting in Post-traumatic Stress Disorder	N/A
Completed	`NCT05112003` - Translingual Neurostimulation for the Virtual Treatment of Post-Traumatic Stress Disorder: A Feasibility Pilot	N/A
Recruiting	`NCT04518267` - Anger and Psychotrauma: Data From Military and Civilians
Completed	`NCT02502604` - Cognitive Training Program for Individuals With Depression and Post-Traumatic Stress Disorder	N/A
Terminated	`NCT02234687` - A mGlu2/3 Agonist in the Treatment of PTSD	Phase 1
Completed	`NCT02256566` - Cognitive Training for Mood and Anxiety Disorders	N/A
Completed	`NCT02213900` - Preventing Post-Operative Delirium in Patients Undergoing a Pneumonectomy, Esophagectomy or Thoracotomy	Phase 4
Completed	`NCT01738308` - The Effects of Healing Touch on Post Operative Pediatric Patients	N/A
Terminated	`NCT02520726` - PTSD Prevention Study Examining the Efficacy of Sertraline in Burn Victims	Phase 4
Completed	`NCT01437891` - Sentra AM® and Sentra PM® for Post-traumatic Stress Disorder (PTSD) and Gulf War Fibromyalgia (GWF)	N/A
Completed	`NCT01517711` - Tramadol Extended-Release (ER) for Posttraumatic Stress Disorder (PTSD)	Phase 4
Completed	`NCT01998100` - Maximizing Treatment Outcome in Post-Traumatic Stress Disorder (PTSD)	Phase 3
Completed	`NCT01199107` - Maximizing Treatment Outcome and Examining Sleep in Post-traumatic Stress Disorder (PTSD)	Phase 3
Completed	`NCT01231711` - Improving Quality-of-life and Depressive Symptoms of Combat Veterans Via Internet-based Intervention	Phase 1
Completed	`NCT00680524` - Telephone-based Care for OEF/OIF Veterans With PTSD	N/A
Completed	`NCT00348036` - Group Intervention for Interpersonal Trauma	N/A
Completed	`NCT00838006` - Psychophysiologic Predictors of Post-deployment Mental Health Outcomes	N/A
Completed	`NCT00525226` - Evaluating the Effects of Stress in Pregnancy	N/A
Completed	`NCT00127673` - Comparison of Two Treatments for Post-Traumatic Stress Disorder	Phase 3
Completed	`NCT00183690` - Prolonged Exposure Therapy Versus Active Psychotherapy in Treating Post-Traumatic Stress Disorder in Adolescents	Phase 1

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.